{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:44:21Z","timestamp":1781664261215,"version":"3.54.5"},"reference-count":31,"publisher":"Galenos Yayinevi","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjo"],"DOI":"10.4274\/tjo.galenos.2025.86584","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:15:07Z","timestamp":1745561707000},"page":"61-66","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from T\u00fcrkiye"],"prefix":"10.4274","volume":"55","author":[{"given":"Nilay","family":"Akag\u00fcn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur Emrah","family":"Alt\u0131parmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","unstructured":"1. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036-1042.","journal-title":"Ophthalmology"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","article-title":"The complications of myopia: a review and meta-analysis","volume":"61","author":"Haarman","year":"2020","unstructured":"2. Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020;61:49.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s00417-018-4112-8","article-title":"Short-term effects of low-concentration atropine eye drops on pupil size and accommodation in young adult subjects","volume":"256","author":"Kaymak","year":"2018","unstructured":"3. Kaymak H, Fricke A, Mauritz Y, L\u00f6winger A, Klabe K, Breyer D, Lagenbucher A, Seitz B, Schaeffel F. Short-term effects of low-concentration atropine eye drops on pupil size and accommodation in young adult subjects. Graefes Arch Clin Exp Ophthalmol. 2018;256:2211-2217.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/opo.12722","article-title":"01% atropine with orthokeratology (AOK) study: a randomised clinical trial","volume":"40","author":"Tan","year":"2020","unstructured":"4. Tan Q, Ng AL, Choy BN, Cheng GP, Woo VC, Cho P. One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt. 2020;40:557-566.","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/OPX.0000000000001884","article-title":"01% atropine with soft multifocal contact lenses on myopia progression in children","volume":"99","author":"Jones","year":"2022","unstructured":"5. Jones JH, Mutti DO, Jones-Jordan LA, Walline JJ. Effect of combining 0.01% atropine with soft multifocal contact lenses on myopia progression in children. Optom Vis Sci. 2022;99:434-442.","journal-title":"Optom Vis Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4103\/tjo.tjo_31_22","article-title":"Myopia control utilizing low-dose atropine as an isolated therapy or in combination with other optical measures: a retrospective cohort study","volume":"13","author":"Erdinest","year":"2023","unstructured":"6. Erdinest N, London N, Lavy I, Levinger N, Pras E, Morad Y. Myopia control utilizing low-dose atropine as an isolated therapy or in combination with other optical measures: a retrospective cohort study. Taiwan J Ophthalmol. 2023;13:231-237.","journal-title":"Taiwan J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"01% doses (atropine for the treatment of myopia 2)","volume":"119","author":"Chia","year":"2012","unstructured":"7. Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology. 2012;119:347-354.","journal-title":"Ophthalmology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.mehy.2007.07.023","article-title":"Light, literacy and the absence of ultraviolet radiation in the development of myopia","volume":"70","author":"Prepas","year":"2008","unstructured":"8. Prepas SB. Light, literacy and the absence of ultraviolet radiation in the development of myopia. Med Hypotheses. 2008;70:635-637.","journal-title":"Med Hypotheses"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.5455\/medscience.2022.12.273","article-title":"Effects of three different doses of atropine drops on myopic progression in children during the coronavirus disease 2019 pandemic","volume":"12","author":"Karakaya","year":"2023","unstructured":"9. Karakaya C, Y\u0131ld\u0131r\u0131m I, \u00d6ztekin A. Effects of three different doses of atropine drops on myopic progression in children during the coronavirus disease 2019 pandemic. Med Sci. 2023;12:393-397.","journal-title":"Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.14744\/bej.2022.07742","article-title":"Role of atropine in the control of myopia progression- a review","volume":"7","author":"Kaiti","year":"2022","unstructured":"10. Kaiti R, Shyangbo R, Sharma IP. Role of atropine in the control of myopia progression- a review. Beyoglu Eye J. 2022;7:157-166.","journal-title":"Beyoglu Eye J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis","volume":"135","author":"Gong","year":"2017","unstructured":"11. Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G, Liu L. Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis. JAMA Ophthalmol. 2017;135:624-630.","journal-title":"JAMA Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s13104-022-06240-8","article-title":"Hospital-prepared low-dose atropine eye drops for myopia progression control using atropine sulfate injection diluted in normal saline and lubricants","volume":"15","author":"Wongwirawat","year":"2022","unstructured":"12. Wongwirawat N, Kuchonthara N, Boontanomwong S, Pongpirul K. Hospital-prepared low-dose atropine eye drops for myopia progression control using atropine sulfate injection diluted in normal saline and lubricants. BMC Res Notes. 2022;15:342.","journal-title":"BMC Res Notes"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.oftal.2017.12.015","article-title":"A 5 year study of safety and effectiveness","volume":"93","author":"Diaz-Llopis","year":"2018","unstructured":"13. Diaz-Llopis M, Pinazo-Dur\u00e1n MD. Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness. Arch Soc Esp Oftalmol (Engl Ed). 2018;93:182-185.","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/aos.14166","article-title":"01% for the treatment of childhood myopia in European patients","volume":"97","author":"Sacchi","year":"2019","unstructured":"14. Sacchi M, Serafino M, Villani E, Tagliabue E, Luccarelli S, Bonsignore F, Nucci P. Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients. Acta Ophthalmol. 2019;97:1136-1140.","journal-title":"Acta Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"21748","DOI":"10.1038\/s41598-021-00923-1","article-title":"01% in childhood myopia progression","volume":"11","author":"P\u00e9rez-Flores I","year":"2021","unstructured":"15. P\u00e9rez-Flores I, Mac\u00edas-Murelaga B, Barrio-Barrio J; Multicenter Group of Atropine Treatment for Myopia Control (GTAM). A multicenter Spanish study of atropine 0.01% in childhood myopia progression. Sci Rep. 2021;11:21748.","journal-title":"Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.jfo.2021.07.005","article-title":"01% eye-drops","volume":"44","author":"Moriche-Carretero","year":"2021","unstructured":"16. Moriche-Carretero M, Revilla-Amores R, Diaz-Valle D, Morales-Fern\u00e1ndez L, Gomez-de-Lia\u00f1o R. Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops. J Fr Ophtalmol. 2021;44:1499-1504.","journal-title":"J Fr Ophtalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1007\/s00417-021-05254-5","article-title":"01% atropine on axial length growth in children in a real-life clinical setting","volume":"259","author":"Kaymak","year":"2021","unstructured":"17. Kaymak H, Graff B, Schaeffel F, Langenbucher A, Seitz B, Schwahn H. A retrospective analysis of the therapeutic effects of 0.01% atropine on axial length growth in children in a real-life clinical setting. Graefes Arch Clin Exp Ophthalmol. 2021;259:3083-3092.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3390\/jcm10071444","article-title":"The effect of long-term low-dose atropine on refractive progression in myopic Australian school children","volume":"10","author":"Myles","year":"2021","unstructured":"18. Myles W, Dunlop C, McFadden SA. The effect of long-term low-dose atropine on refractive progression in myopic Australian school children. J Clin Med. 2021;10:1444.","journal-title":"J Clin Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.12688\/hrbopenres.12914.1","article-title":"Myopia outcome study of atropine in children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol","volume":"2","author":"McCrann","year":"2019","unstructured":"19. McCrann S, Flitcroft I, Strang NC, Saunders KJ, Logan NS, Lee SS, Mackey DA, Butler JS, Loughman J. Myopia outcome study of atropine in children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol. HRB Open Res. 2019;2:15.","journal-title":"HRB Open Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40123-019-0194-6","article-title":"01% atropine in German schoolchildren with progressive myopia","volume":"8","author":"Joachimsen","year":"2019","unstructured":"20. Joachimsen L, B\u00f6hringer D, Gross NJ, Reich M, Stifter J, Reinhard T, Lagr\u00e8ze WA. A pilot study on the efficacy and safety of 0.01% atropine in German schoolchildren with progressive myopia. Ophthalmol Ther. 2019;8:427-433.","journal-title":"Ophthalmol Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/jop.2015.0043","article-title":"01% eyedrops significantly reduce the progression of childhood myopia","volume":"31","author":"TY","year":"2015","unstructured":"21. Clark TY, Clark RA. Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia. J Ocul Pharmacol Ther. 2015;31:541-545.","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3390\/jpm14020175","article-title":"1% loading dose for myopia progression reduction in danish children: a placebo-controlled, randomized clinical trial","volume":"14","author":"Hansen","year":"2024","unstructured":"22. Hansen NC, Hvid-Hansen A, M\u00f8ller F, Bek T, Larsen DA, Jacobsen N, Kessel L. Two-year results of 0.01% atropine eye drops and 0.1% loading dose for myopia progression reduction in danish children: a placebo-controlled, randomized clinical trial. J Pers Med. 2024;14:175.","journal-title":"J Pers Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1547-5069.2003.tb00001.x","article-title":"Adherence to long-term therapies: evidence for action","volume":"35","author":"Burkhart","year":"2003","unstructured":"23. Burkhart PV, Sabat\u00e9 E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh. 2003;35:207.","journal-title":"J Nurs Scholarsh"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304-314.","DOI":"10.4065\/mcp.2010.0575"},{"key":"ref24","unstructured":"25. Khan H, Mahsood YJ, Gul N, Ilyas O, Jan S, Mahsood YJ. Factors responsible for non-compliance of glaucoma patients to topical medications in our setup. Pak J Ophthalmol. 2018;34:272-278."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fphar.2018.01290","article-title":"A systematic review of medication adherence thresholds dependent of clinical outcomes","volume":"9","author":"Baumgartner","year":"2018","unstructured":"26. Baumgartner PC, Haynes RB, Hersberger KE, Arnet I. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front Pharmacol. 2018;9:1290.","journal-title":"Front Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.2147\/PPA.S118121","article-title":"Factors affecting medication adherence in elderly people","volume":"10","author":"Jin","year":"2016","unstructured":"27. Jin H, Kim Y, Rhie SJ. Factors affecting medication adherence in elderly people. Patient Prefer Adherence. 2016;10:2117-21125.","journal-title":"Patient Prefer Adherence"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12886-016-0316-z","article-title":"Level of adherence to ocular hypotensive agents and its determinant factors among glaucoma patients in Menelik II Referral Hospital, Ethiopia","volume":"16","author":"Mehari","year":"2016","unstructured":"28. Mehari T, Giorgis AT, Shibeshi W. Level of adherence to ocular hypotensive agents and its determinant factors among glaucoma patients in Menelik II Referral Hospital, Ethiopia. BMC Ophthalmol. 2016;16:131.","journal-title":"BMC Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.12669\/pjms.323.9799","article-title":"Medication adherence to oral iron therapy in patients with iron deficiency anemia","volume":"32","author":"Gereklioglu","year":"2016","unstructured":"29. Gereklioglu C, Asma S, Korur A, Erdogan F, Kut A. Medication adherence to oral iron therapy in patients with iron deficiency anemia. Pak J Med Sci. 2016;32:604-607.","journal-title":"Pak J Med Sci"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Aljofan M, Oshibayeva A, Moldaliyev I, Saruarov Y, Maulenkul T, Gaipov A. The rate of medication nonadherence and influencing factors: a systematic review. Electron J Gen Med. 2023;20:em471.","DOI":"10.29333\/ejgm\/12946"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5001\/omj.2011.38","article-title":"Patient medication adherence: measures in daily practice","volume":"26","author":"Jimmy","year":"2011","unstructured":"31. Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26:155-159.","journal-title":"Oman Med J"}],"container-title":["Turkish Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T14:10:33Z","timestamp":1747231833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oftalmoloji.org\/articles\/evaluation-of-reasons-for-discontinuation-of-atropine-001percent-in-myopia-management-a-single-center-retrospective-study-from-turkiye\/doi\/tjo.galenos.2025.86584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4,25]]}},"URL":"https:\/\/doi.org\/10.4274\/tjo.galenos.2025.86584","relation":{},"ISSN":["1300-0659","2147-2661"],"issn-type":[{"value":"1300-0659","type":"print"},{"value":"2147-2661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}